VDR and breast carcinoma: In a follow‐up study, 1,25D binding sites were detected in breast and lymph node tissue from 7 of 10 patients with breast cancer and in patients with benign neoplasms.(2) Cloning of the hVDR cDNA and generation of anti‐VDR monoclonal antibodies eventually confirmed that the majority of human breast tumors express VDR mRNA and protein, although the relationship between its expression and clinical outcomes remains unclear as discussed below.(3)